{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:59:11Z","timestamp":1787237951919,"version":"build-2736575974"},"reference-count":115,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.eimc.2013.02.001","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T07:45:21Z","timestamp":1364543121000},"page":"672-684","source":"Crossref","is-referenced-by-count":12,"title":["Recomendaciones de GESIDA\/Secretar\u00eda del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero de 2013)"],"prefix":"10.1016","volume":"31","author":[{"given":"Antonio","family":"Rivero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Cayl\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"P\u00e9rez-Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2013.02.001_bib0005","unstructured":"World Health Organization. Global tuberculosis report 2012. Geneva, Switzerland: World Health Organization [consultado 21 Oct 2012]. Disponible en: http:\/\/www.who.int\/tb\/publications\/global_report\/en\/index.html"},{"key":"10.1016\/j.eimc.2013.02.001_bib0010","first-page":"1","article-title":"Estudio transversal multihospitalario de tuberculosis y resistencias en Madrid (octubre de 1993-abril de 1994)","volume":"106","year":"1996","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2013.02.001_bib0015","series-title":"XIX International AIDS Conference","article-title":"Tuberculosis in a cohort of HIV-positive subjects in Spain: Presentation, clinical practice and treatment outcomes","author":"Sizaire","year":"2012"},{"key":"10.1016\/j.eimc.2013.02.001_bib0020","first-page":"1393","article-title":"Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status","volume":"12","author":"Moreno","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.eimc.2010.02.006","article-title":"Documento de consenso sobre diagn\u00f3stico, tratamiento y prevenci\u00f3n de la tuberculosis","volume":"28","author":"Gonz\u00e1lez-Mart\u00edn","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1157\/13123842","volume":"26","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.02.001_bib0040","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.02.001_bib0045","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/bmj.a744","article-title":"Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.02.001_bib0050","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","article-title":"Incorporating considerations of resources use into grading recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.02.001_bib0055","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.02.001_bib0060","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2013.02.001_bib0065","first-page":"1","article-title":"Treatment of tuberculosis","volume":"52","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.eimc.2013.02.001_bib0070","series-title":"Anti-tuberculosis drug resistance in the world: fourth global report","year":"2008"},{"key":"10.1016\/j.eimc.2013.02.001_bib0075","first-page":"22","article-title":"Situaci\u00f3n de las resistencias a f\u00e1rmacos de Mycobacterium tuberculosis en Espa\u00f1a","volume":"21","author":"Jim\u00e9nez","year":"2008","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.eimc.2013.02.001_bib0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.eimc.2010.02.011","article-title":"Resistencias a f\u00e1rmacos de Mycobacterium tuberculosis en la Comunidad de Castilla y Le\u00f3n (Espa\u00f1a), 2001-2005: tercer estudio multic\u00e9ntrico","volume":"28","author":"Alberte-Casti\u00f1eiras","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0014-2565(09)72631-1","article-title":"An\u00e1lisis de la poblaci\u00f3n atendida en una unidad de tuberculosis en Madrid. Evoluci\u00f3n e impacto de la inmigraci\u00f3n desde 1997 a 2006","volume":"209","author":"Soler Rangel","year":"2009","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.eimc.2013.02.001_bib0090","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eimc.2011.04.002","article-title":"Changes in the epidemiology of tuberculosis: the influence of international migration flows","volume":"29","author":"Fort\u00fan","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0095","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1157\/13106563","article-title":"Situaci\u00f3n actual de las resistencias de Mycobacterium tuberculosis en la poblaci\u00f3n inmigrante de la Comunidad de Madrid","volume":"43","author":"Sanz Barbero","year":"2007","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.eimc.2013.02.001_bib0100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1157\/13089102","article-title":"Impacto de la inmigraci\u00f3n en las resistencias de Mycobacterium tuberculosis en la provincia de Castell\u00f3n: 1995-2003","volume":"126","author":"Tirado Balaguer","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2013.02.001_bib0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0962-8479(05)80007-3","article-title":"A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis","volume":"76","author":"Schwander","year":"1995","journal-title":"Tubercle Lung Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/313771","article-title":"Use of rifabutin with protease inhibitors for human immunodeficiency virus infected patients with tuberculosis","volume":"30","author":"Narita","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0115","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"Boulanger","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0120","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/598336","article-title":"Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy","volume":"48","author":"Jenny-Avital","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0125","unstructured":"World Health Organization. Treatment of tuberculosis: guidelines. 2010, 4th ed. World Health Organization Web site [consultado 21 Oct 2012]. Disponible en: http:\/\/www.who.int\/tb\/publications\/tb_treatmentguidelines\/en\/index.html"},{"key":"10.1016\/j.eimc.2013.02.001_bib0130","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cis630","article-title":"An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection","volume":"55","author":"Khan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0135","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.200903-0439OC","article-title":"Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial","volume":"181","author":"Swaminathan","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0140","first-page":"214","article-title":"Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens","volume":"51","year":"2002","journal-title":"MMWR"},{"key":"10.1016\/j.eimc.2013.02.001_bib0145","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1086\/520275","article-title":"Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus related pulmonary tuberculosis","volume":"26","author":"El-Sadr","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/381675","article-title":"Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use","volume":"38","author":"Nettles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0155","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice weekly treatment of HIV-related tuberculosis","volume":"173","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0160","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis-treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2013.02.001_bib0165","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2011.436","article-title":"Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: The Study C randomized controlled trial","volume":"305","author":"Lienhardt","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2013.02.001_bib0170","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/427995","article-title":"Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: A phase 2 clinical trial in Uganda","volume":"191","author":"Mayanja-Kizza","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0175","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/422257","article-title":"A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis","volume":"190","author":"Elliott","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0180","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001876.pub2","article-title":"Corticosteroids for tuberculous pleurisy","author":"Engel","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2013.02.001_bib0185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002244.pub3","article-title":"Corticosteroids for managing tuberculous meningitis","author":"Prasad","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2013.02.001_bib0190","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0195","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/heart.84.2.183","article-title":"Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients","volume":"84","author":"Hakim","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.eimc.2013.02.001_bib0200","first-page":"233","article-title":"Experience with adjunctive corticosteroids in managing tuberculous pericarditis","volume":"17","author":"Reuter","year":"2006","journal-title":"Cardiovasc J S Afr"},{"key":"10.1016\/j.eimc.2013.02.001_bib0205","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Meintjes","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2011.00954.x","article-title":"British HIV Association guidelines for the treatment of TB\/VIH coinfection 2011","volume":"12","author":"Pozniak","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archinte.1997.00440230105014","article-title":"Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients","volume":"157","author":"Pulido","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0220","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1164\/rccm.200509-1529OC","article-title":"Treatment outcomes of patients with HIV and tuberculosis","volume":"175","author":"Nahid","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0225","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJM199503233321204","article-title":"Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months","volume":"332","author":"Perriens","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0230","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/ajrccm.154.4.8887603","article-title":"Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection","volume":"154","author":"Chaisson","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0235","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/00002030-199910010-00012","article-title":"Relapse rates after short-course (6-month) treatment of tuberculosis in HIV infected and uninfected persons","volume":"13","author":"Sterling","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0240","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00002030-199510000-00011","article-title":"Two-year follow up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa","volume":"9","author":"Kassim","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0245","first-page":"263","article-title":"Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment","volume":"15","author":"Catal\u00e0","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0250","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/QAD.0b013e328311ac4e","article-title":"Recurrent tuberculosis in HIV infected patients in Rio de Janeiro, Brazil","volume":"22","author":"Golub","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0255","unstructured":"Bureau of Tuberculosis Control. New York City Department of Health and Mental Hygiene. Clinical Policies and Protocols. 4th edition March 2008 [consultado 21 Oct 2012]. Disponible en: http:\/\/www.nyc.gov\/html\/doh\/downloads\/pdf\/tb\/tb-protocol.pdf"},{"key":"10.1016\/j.eimc.2013.02.001_bib0260","first-page":"1028","article-title":"Tuberculous meningitis: is a 6-month treatment regimen sufficient?","volume":"5","author":"Loenhout-Rooyackers","year":"2001","journal-title":"Int J Tub Lung Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0265","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of anti-tuberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0270","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4102\/sajhivmed.v12i1.214","article-title":"The risks of concurrent treatment with tenofovir and aminoglycosides in patients with HIV-associated tuberculosis","volume":"12","author":"Kenyon","year":"2011","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0280","unstructured":"McIlleron H, Martinson N, Denti P, Mashabela F, Hunt J, Shembe S, et al. Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral therapy (ART) with and without rifampin-containing tuberculosis (TB) treatment. 19th International Conference on AIDS, abstract MOAB0303, Washington, DC, July 2012."},{"key":"10.1016\/j.eimc.2013.02.001_bib0285","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eimc.2008.10.008","article-title":"Documento de consenso para el tratamiento de la tuberculosis en pacientes con trasplante de \u00f3rgano s\u00f3lido","volume":"27","author":"Aguado","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0290","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1183\/09031936.98.12040967","article-title":"Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release","volume":"12","author":"Marco","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eimc.2013.02.001_bib0295","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1086\/424676","article-title":"Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy","volume":"190","author":"Dheda","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0300","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0305","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0310","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0315","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0320","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2013.02.001_bib0325","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis","volume":"52","author":"T\u00f6r\u00f6k","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0330","unstructured":"World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 revision). Geneva, Switzerland: World Health Organization [consultado 21 Oct 2012]. Disponible en: http:\/\/www.who.int\/hiv\/pub\/arv\/adult2010\/en\/"},{"key":"10.1016\/j.eimc.2013.02.001_bib0335","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.eimc.2012.03.006","article-title":"Recomendaciones de GESIDA\/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero de 2012)","volume":"30","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0340","unstructured":"Department of Human Health Service Panel on Antiretroviral Guidelines for Adults and Adolescents. Guideline for the use of antiretroviral agents in HIV-1-infected adults and adolescents: March 27, 2012 [consultado 21 Oct 2012]. Disponible en: http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf"},{"key":"10.1016\/j.eimc.2013.02.001_bib0345","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2013.02.001_bib0350","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00002030-200303070-00024","article-title":"Co-administration of rifampin and nevirapine inHIV-infected patients with tuberculosis","volume":"17","author":"Oliva","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0355","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interaction between efavirenz and rifampin in HIV-infected patients with tuberculosis","volume":"41","author":"L\u00f3pez-Cort\u00e9s","year":"2002","journal-title":"Clin Pharmacokinetic"},{"key":"10.1016\/j.eimc.2013.02.001_bib0360","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","article-title":"Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis","volume":"28","author":"Ribera","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2013.02.001_bib0365","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl357","article-title":"Efavirenz trough levels are not associated with virological failure throughout therapy with 800mg daily and a rifampicin-containing anti-tuberculosis regimen","volume":"58","author":"L\u00f3pez-Cort\u00e9s","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0370","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkl399","article-title":"Administration of efavirenz (600mg\/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV","volume":"58","author":"Friedland","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0375","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350801300414","article-title":"Pharmacokinetics and 48-week efficacy of nevirapine: 400mg versus 600mg per day in HIV-tuberculosis coinfection receiving rifampicin","volume":"13","author":"Avihingsanon","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2013.02.001_bib0380","first-page":"197","article-title":"Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi","volume":"14","author":"Moses","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0385","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600mg\/day versus efavirenz 800mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0390","first-page":"360","article-title":"Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana","volume":"13","author":"Shipton","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0395","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1086\/599115","article-title":"Efavirenz and nevirapine interactions with rifampin: resolving the dilemmas?","volume":"48","author":"Lalloo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0400","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 non nucleoside reverse transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0405","doi-asserted-by":"crossref","unstructured":"Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother 68:2016;250\u20136.","DOI":"10.1093\/jac\/dks404"},{"key":"10.1016\/j.eimc.2013.02.001_bib0410","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11534740-000000000-00000","article-title":"Pharmacokinetic interactions between etravirine and non-antiretroviral drugs","volume":"50","author":"Kakuda","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2013.02.001_bib0415","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1128\/AAC.01468-08","article-title":"Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir","volume":"57","author":"Wenning","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0420","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2013.02.001_bib0425","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1128\/AAC.01543-07","article-title":"Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir","volume":"52","author":"Iwamoto","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0430","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1128\/AAC.00487-08","article-title":"Minimal pharmacokinetic interaction between the human immunodeficiency virus non nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects","volume":"52","author":"Anderson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0435","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/AAC.01486-08","article-title":"Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir","volume":"53","author":"Hanley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0440","series-title":"19th International Conference on AIDS","article-title":"A randomised trial to estimate efficacy and safety of 2 doses of raltegravir and efavirenz for treatment of HIV-TB co-infected patients: ANRS 12 180 REFLATE TB trial","author":"De Castro","year":"2012"},{"key":"10.1016\/j.eimc.2013.02.001_bib0445","unstructured":"FDA. Isentress; Prescribing Information. Version July 8, 2009"},{"key":"10.1016\/j.eimc.2013.02.001_bib0450","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Isentress: Ficha t\u00e9cnica. Marzo, 2010"},{"key":"10.1016\/j.eimc.2013.02.001_bib0455","unstructured":"Elvitegravir\/cobicistat (Stribild) [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2012"},{"key":"10.1016\/j.eimc.2013.02.001_bib0460","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2013.02.001_bib0465","unstructured":"The European Medicines Agency (EMEA). Celsentri: EPAR \u2014 Product Information [consultado 21 Oct 2012]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000811\/WC500022190.pdf"},{"key":"10.1016\/j.eimc.2013.02.001_bib0470","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e318189a7df","article-title":"Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir","volume":"50","author":"Haas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2013.02.001_bib0475","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/QAD.0b013e3282faa71e","article-title":"High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir\/ritonavir tablets","volume":"22","author":"Nijland","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0480","first-page":"32","article-title":"Drug-induced hepatitis with saquinavir\/ritonavir + rifampin","volume":"17","year":"2005","journal-title":"AIDS Clin Care"},{"key":"10.1016\/j.eimc.2013.02.001_bib0485","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1378\/chest.114.3.933","article-title":"Paradoxical reactions in HIV and pulmonary TB","volume":"114","author":"Chien","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.eimc.2013.02.001_bib0490","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/595006","article-title":"HIV\/AIDS: immune reconstitution inflammatory syndrome: are appraisal","volume":"48","author":"French","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0495","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings","volume":"8","author":"Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0500","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/QAD.0b013e32832ec1f4","article-title":"Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"Haddow","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0505","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-157-5-201209040-00004","article-title":"The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: Findings from the SAPiT trial","volume":"157","author":"Naidoo","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0510","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2006.01.002","article-title":"Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy","volume":"53","author":"Manosuthi","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2013.02.001_bib0515","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0b013e328011efac","article-title":"Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa","volume":"21","author":"Lawn","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0520","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/cid\/cis899","article-title":"Frequency, severity and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome","volume":"56","author":"Marais","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0525","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/QAD.0b013e328358daea","article-title":"Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS","volume":"26","author":"Brunel","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.02.001_bib0530","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/317547","article-title":"High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B","volume":"32","author":"Rivero","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2013.02.001_bib0535","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jama.1996.03540150031027","article-title":"A multi-institutional outbreak of highly drug-resistant tuberculosis: Epidemiology and clinical outcomes","volume":"276","author":"Frieden","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2013.02.001_bib0540","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(04)15496-2","article-title":"Programmes and principles in treatment of multidrug-resistant tuberculosis","volume":"363","author":"Mukherjee","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2013.02.001_bib0545","first-page":"1176","article-title":"Revised definition of extensively drug resistant tuberculosis","volume":"55","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Supl 1","key":"10.1016\/j.eimc.2013.02.001_bib0550","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0213-005X(11)70017-9","article-title":"Present-day treatment of tuberculosis and latent tuberculosis infection","volume":"29","author":"Perez-Camacho","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.02.001_bib0555","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2013.02.001_bib0560","series-title":"Proceedings of the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease","article-title":"TMC-207 versus placebo plus OBT for the treatment of MDR-TB: A prospective clinical trial","author":"McNeeley","year":"2010"},{"key":"10.1016\/j.eimc.2013.02.001_bib0565","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2013.02.001_bib0570","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2013.02.001_bib0575","series-title":"Proceedings of the 3rd International Workshop on Clinical Pharmacology of TB Drugs","article-title":"Population PK-PD modeling of phase 1 data of PNU-100480 to guide doses for phase 2a study","author":"Kumar","year":"2010"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X13000232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X13000232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T14:54:18Z","timestamp":1688136858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X13000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":115,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0213005X13000232"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2013.02.001","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}